Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia

NACompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

December 20, 2020

Study Completion Date

June 23, 2021

Conditions
Covid19Pneumonia
Interventions
PROCEDURE

Combined use of a respiratory broad panel multiplex PCR and procalcitonin

The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.

OTHER

Usual antibiotic treatment

The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.

Trial Locations (1)

75020

Intensive care department-Hospital Tenon, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMérieux

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04334850 - Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter